Enanta Pharmaceuticals ABT-493 has potential, says JMP Securities After examining data on Enanta's protease inhibitor, ABT-493. JMP Securities is encouraged by the drug's potential, as the firm thinks it can be competitive in the HCV space. The firm reiterates a $50 price target and Outperform rating on the shares.
News For ENTA From The Last 14 Days
Check below for free stories on ENTA the last two weeks.